CD70-Targeted Radiotheranostics: Now and Future.

IF 5.9 2区医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Seminars in nuclear medicine Pub Date : 2025-09-18 DOI:10.1053/j.semnuclmed.2025.08.001

Binyu Shi, Xinyuan Zhou, Junjun Zhou, Gang Huang, Jianjun Liu, Jin Zhang, Weijun Wei

{"title":"CD70-Targeted Radiotheranostics: Now and Future.","authors":"Binyu Shi, Xinyuan Zhou, Junjun Zhou, Gang Huang, Jianjun Liu, Jin Zhang, Weijun Wei","doi":"10.1053/j.semnuclmed.2025.08.001","DOIUrl":null,"url":null,"abstract":"<p><p>The cluster of differentiation 70 (CD70), a transmembrane glycoprotein encoded by TNFSF7, is a member of the tumor necrosis factor (TNF) superfamily and serves as the ligand for the co-stimulatory receptor CD27. It is aberrantly overexpressed in various malignancies, including clear cell renal cell carcinoma (ccRCC) and nasopharyngeal carcinoma (NPC). Although CD70-directed radiotheranostics may address key challenges faced by antibody-drug conjugates (ADCs) and chimeric antigen receptor T (CAR-T) therapies, such as drug resistance and tumor penetration barriers, this therapeutic approach remains unexplored in clinical settings. In this review, we highlight the expression of CD70 in normal tissues and organs, as well as in different tumor types, presenting promising results from CD70-targeted immuno-PET/CT imaging in recent clinical trials. Furthermore, we emphasize relevant therapeutic radiopharmaceuticals currently in preclinical or clinical trials, providing a rational roadmap for guiding future development of CD70-targeted radiotheranostics.</p>","PeriodicalId":21643,"journal":{"name":"Seminars in nuclear medicine","volume":" ","pages":""},"PeriodicalIF":5.9000,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in nuclear medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1053/j.semnuclmed.2025.08.001","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

Abstract

The cluster of differentiation 70 (CD70), a transmembrane glycoprotein encoded by TNFSF7, is a member of the tumor necrosis factor (TNF) superfamily and serves as the ligand for the co-stimulatory receptor CD27. It is aberrantly overexpressed in various malignancies, including clear cell renal cell carcinoma (ccRCC) and nasopharyngeal carcinoma (NPC). Although CD70-directed radiotheranostics may address key challenges faced by antibody-drug conjugates (ADCs) and chimeric antigen receptor T (CAR-T) therapies, such as drug resistance and tumor penetration barriers, this therapeutic approach remains unexplored in clinical settings. In this review, we highlight the expression of CD70 in normal tissues and organs, as well as in different tumor types, presenting promising results from CD70-targeted immuno-PET/CT imaging in recent clinical trials. Furthermore, we emphasize relevant therapeutic radiopharmaceuticals currently in preclinical or clinical trials, providing a rational roadmap for guiding future development of CD70-targeted radiotheranostics.

查看原文本刊更多论文

cd70靶向放射治疗：现在与未来。

分化簇70 （CD70）是一种由TNFSF7编码的跨膜糖蛋白，是肿瘤坏死因子（TNF）超家族的成员，并作为共刺激受体CD27的配体。它在各种恶性肿瘤中异常过表达，包括透明细胞肾细胞癌（ccRCC）和鼻咽癌（NPC）。尽管cd70定向放射治疗可能解决抗体-药物偶联物（adc）和嵌合抗原受体T （CAR-T）疗法面临的关键挑战，如耐药性和肿瘤穿透屏障，但这种治疗方法在临床环境中仍未被探索。在这篇综述中，我们重点介绍了CD70在正常组织和器官以及不同肿瘤类型中的表达，并在最近的临床试验中展示了CD70靶向免疫pet /CT成像的令人鼓舞的结果。此外，我们还重点介绍了目前处于临床前或临床试验阶段的相关治疗性放射药物，为指导cd70靶向放射治疗学的未来发展提供了合理的路线图。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Seminars in nuclear medicine 医学-核医学

CiteScore

9.80

自引率

6.10%

发文量

审稿时长

14 days

期刊介绍： Seminars in Nuclear Medicine is the leading review journal in nuclear medicine. Each issue brings you expert reviews and commentary on a single topic as selected by the Editors. The journal contains extensive coverage of the field of nuclear medicine, including PET, SPECT, and other molecular imaging studies, and related imaging studies. Full-color illustrations are used throughout to highlight important findings. Seminars is included in PubMed/Medline, Thomson/ISI, and other major scientific indexes.